I think can ignore that press, it is about fighter jets and helicopters. Will still search
Found something more relevant on the Military contracts. From what I can understand, Inventus Power is the company that has the agreement with the US military but they seems like the source batteries from different vendors like below:
The timeline seems to be similar to what Enovix was providing:
â Amprius remains committed to working closely with its partner, Inventus Power, to deliver these Conformal Wearable Batteries (âCWBâ) packs to the US Army before the end of 2023.â
And expects to go until 2030:
â These advancements are part of a larger program (U.S. Department of Defense Contract), which outlined Inventus Power as a participant in a competition to supply conformal wearable batteries to the U.S. Army. This program represents a significant opportunity, with a total value of $1.25 billion through 2030.â
Then the question is how much of that 1.2B goes to Inventus and who does Inventus select for batteriesâŚ
2 Likes
Added:
AOSL to the Roster with a Development squad level position
Added To:
SMCI
CRWD
NVDA
The portfolio has not yet entered Hunker Down territory - if it does then the next level after that would be Retreat to High Ground.
All the Best,
3 Likes
Hi jdc115
Thanks for posting the additional data.
We should know a lot more after earnings.
All the Best,
Sold Shares I added yesterday as follows:
SMCI for a one day gain of 7.94%
NVDA for a one day gain of 7.85%
Itâs good to be back in business.
All the Best
4 Likes
3). Palantir Technologies
PLTR
Palantir Technologies Inc. builds and deploys software platforms for the intelligence community to assist in counterterrorism investigations and operations in the United States, the United Kingdom, and internationally. The company provides Palantir Gotham, a software platform which enables users to identify patterns hidden deep within datasets, ranging from signals intelligence sources to reports from confidential informants, as well as facilitates the handoff between analysts and operational users, helping operators plan and execute real-world responses to threats that have been identified within the platform. It also offers Palantir Foundry, a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place. In addition, it provides Palantir Apollo, a software that delivers software and updates across the business, as well as enables customers to deploy their software virtually in any environment; and Palantir Artificial Intelligence Platform (AIP) that provides unified access to open-source, self-hosted, and commercial large language models (LLM) that can transform structured and unstructured data into LLM-understandable objects and can turn organizationsâ actions and processes into tools for humans and LLM-driven agents.
Current Data Points:
Current Price: $27.10 (Intraday)
52 Wk Range: 13.68 - 29.83
About 9% Below its High
30 Day Momentum: 7.11%
YTD Momentum: 57.85%
Market Cap: $60B Give or Take
EV/Sales FWD: 20.50
The company last reported with FQ1 2024 way back on May 6 with Y/Y Revenue
coming in at 20.8%. Here is that report:
Highlights:
- Revenue grew 21% year-over-year and 4% quarter-over-quarter to $634 million
- US Commercial Highlights
-
US commercial revenue grew 40% year-over-year and 14% quarter-over-quarter to $150 million
-
US commercial customer count grew 69% year-over-year and 19% quarter-over-quarter to 262 customers
-
US commercial remaining deal value (âRDVâ) grew 74% year-over-year and 14% quarter-over-quarter
-
Commercial revenue grew 27% year-over-year and 5% quarter-over-quarter to $299 million
- Government Stuff
-
Government revenue grew 16% year-over-year and 3% quarter-over-quarter to $335 million
-
US government revenue grew 12% year-over-year and 8% quarter-over-quarter to $257 million
Note: I separated Commercial progress from Government progress due to negative perception and questions concerning the companies ability to develop its Commercial offerings. It did and seems to have put that concern to bed - at least for the time being.
-
Customer count grew 42% year-over-year and 11% quarter-over-quarter
-
Adjusted income from operations of $226 million, representing a margin of 36%
-
Sixth consecutive quarter of expanding adjusted operating margins
-
Rule of 40 score of 57%
-
Cash from operations of $130 million, representing a 20% margin
-
Adjusted free cash flow of $149 million, representing a 23% margin
CC Transcript Here:
Y/Y Revenue Growth over the Last 4 QTRS:
20.8
19.6
16.8
12.7
Scouting Reports:
If it retreats to the $24-25 range I might add it to the Development Squad. Short of some crisis it probably just wonât.
All the Best,
3 Likes
Enovix reported Q2 after the bell with a solid beats on both Non-GAAP EPS and Revenue Growth. Here is the press release:
One Key Phrase in the Press Release:
- We expect significant revenue growth from the first half of 2024 to the second half of 2024.
Considering adding a bit in the AH market. Maybe.
All the Best,
TransMedics TMDX
Released Q2 2024 results:
A Few Highlights:
-
Total revenue for the second quarter of 2024 was $114.3 million, a 118% increase compared to $52.5 million in the second quarter of 2023. The increase was driven primarily by the increase in utilization of the Organ Care System (âOCSâ˘â) across all three organs through the National OCS Program (âNOPâ˘â) as well as additional revenue generated by the launch of TransMedics logistics services.
-
Gross margin for the second quarter of 2024 was 61%, compared to 70% in the second quarter of 2023. The change from prior year is a result of a higher proportion of service revenue in 2024.
-
Operating expenses for the second quarter of 2024 were $56.8 million, compared to $37.6 million in the second quarter of 2023. The increase in operating expense was driven primarily by increased research and development investment as well as investment throughout the organization to support the growth of the company. Second quarter operating expenses in 2024 included $7.3 million of stock compensation expense compared to $4.9 million of stock compensation expense in the second quarter of 2023.
-
Net income for the second quarter of 2024 was $12.2 million, or 10.7% of revenue, compared to a net loss of $1.0 million in the second quarter of 2023.
-
Owned 15 total aircraft as of June 30, 2024
and Purchased two additional aircraft in July 2024
Raised Guidance:
TransMedics is raising its full year 2024 revenue guidance to be in the range of $425 million to $445 million, which represents 76% to 84% growth compared to the companyâs prior year revenue. TransMedicsâ prior 2024 revenue guidance was $390 million to $400 million.
One Key Quote from the Release:
âWe remain well positioned to successfully execute our 2024 strategy and to launch our new OCS lung and heart clinical programs in 2025.â
Fan Reaction: Stock is up in AH trading by 8.25%.
6 Likes
Took todays carnage as an opportunity to add to:
NU
MELI
SMCI
ZS
All the Best.
2 Likes
MercadoLibre
MELI
After being taken to the woodshed by bailing investors - losing $62.84 per share during regular hours trading, the company reported after the bell today with incredible, remarkable, astoundingly powerful quarterly results. Here is that report:
The company Beat on EPS by $2.00 (Almost a 25% Beat on estimates) and simply crushed Revenue with Y/Y growth of just over 41%.
-
Net revenues & financial income of $5.1 billion, up 42% YoY and 113% FX-
neutral Income from operations of $726 million, with a 14.3% margin -
Net income of $531 million, with a 10.5% margin
*$46.3 billion Total Payment Volume, up 36% YoY and 86% FX-neutral $12.6
billion Gross Merchandise Volume, up 20% YoY and 83% FX-neutral
Letter to Shareholders:
At one point during the day the stock was down just over $88 per share and I picked up a few shares around that price.
Fan Reaction: MELI is currently up $194.00 per share ( +12%) during AH trading.
All the Best,
4 Likes
As I sit here this evening contemplating a plan for tomorrow, I will probably sell the additional MELI shares I picked up today. My purchase price was just below $1600 and ifâŚIF I say⌠the purchase frenzy continues along the lines of $1800 itâs highly likely I will sell the shares I picked up today for a one day gain of a little better than 12%. Weâll see.
2 Likes
The only problem is that they did something like $3m in revenue. A 50% increase in revenue is significant growth but still is pretty much nil⌠and would still consider them pre-revenue.
1 Like
âThe only problem is that they did something like $3m in revenue. A 50% increase in revenue is significant growth but still is pretty much nil⌠and would still consider them pre-revenue.â
They didnât fair very well today and with the futures in the tank tomorrow might not be so good for them either.
With todayâs carnage we have entered both Hunker Down and Retreat to High Ground strategies.
All the Best,
3 Likes
Retreat to High Ground:
Sold AOSL
Sold ENVX
Sold CRWD
Note: Made a big dumb mistake with CRWD. I still think it will recover however, it is probably going to be dead money for a while and there are better places for the funds.
Rolled funds generated from sales into:
NVDA
NU
ELF
SMCI
ZS
All the Best,
5 Likes
Sold the additional shares of MELI purchased yesterday for a short term 10.28% gain.
4 Likes
Really - really considering MMYT here for an entry level position. But there is a catchâŚfly in the ointment to wit:
I have declared Hunker Down and Retreat to High Ground Strategy for the portfolio which precludes me from adding any new companies until the Warning Sirens go quiet. We ainât there yetâŚstillâŚseems like a decent enough entry for a MMYT at this time.
Investing is Hard,
BDH Investing
5 Likes
I would stay away for now Champ, it just gapped down today and the 50 day is starting to roll over. I think staying in your bunker is a smart move till we hear the air sirens quit blowing.
1 Like
I take that as excellent advice. I did get close though.
All the Best,
1 Like
From The Bull and Bear Report:
âHowever, while the markets are oversold enough for a reflexive bounce, the current correction process is likely incomplete. Moreover, the MACD âsell signalâ also suggests that the current upside remains limited.â
âIt is quite likely that any short-term, reflexive rally will fail during this corrective process. For now, use rallies to rebalance portfolios and reduce risk as needed. Our only concern is that with investors remaining very bullish despite the recent pullback, a further correction is required to resolve that condition.â
Inversion Of Yield Curve Finally Reversing
We have discussed the importance of yield curve inversions numerous times. However, regarding a recession countdown, the media always misunderstands the signal. The media always assumes this time is different because a recession didnât occur immediately upon the inversion.
There are two problems with this way of thinking.
- The National Bureau of Economic Research (NBER) is the official recession dating arbiter. It waits for data revisions by the Bureau of Economic Analysis (BEA) before announcing a recessionâs official start. Therefore, the NBER is always 6-12 months late in dating the recession.
- It is not the inversion of the yield curve that denotes the recession. **The inversion is the âwarning sign,â whereas the un-inversion marks the start of the recession, which the NBER will recognize later.
That last sentence is the most important. Regarding a ârecession countdown,â the initial inversion is not the signal. It is when the curves un-invert that a recession is approaching. The reason is that the Federal Reserve is rapidly cutting rates as the recession is recognized. Such causes the short end of the yield curve to fall faster than the long end**.** With the Fed on deck to start cutting rates in September, yields should decline further as economic weakness expands.
Navigating The Pullback
While the economy could avoid a âdeep recession,â the odds of a âno landing scenarioâ are slim. Therefore, we should at least prepare for a slower earnings growth rate as economic activity recedes. The rules are simple but effective.
- Raise cash levels in portfolios.
- Reduce equity risk, particularly in areas highly dependent on economic growth.
- Add or increase the duration of bond allocations, which tend to offset risk during recessionary downturns.
- Reduce exposure to commodities and inflation trades as economic growth slows.
If a recession does occur, the preparation allows you to survive the impact. Protecting capital will mean less time spent getting back to breakeven afterward. Alternatively, it is relatively easy to reallocate funds to equity risk if we avoid a recession and achieve a âsoft landing.â
Investing during periods of economic reversion can be difficult. However, you can take steps to ensure that increased volatility is survivable.
- Have excess emergency savings, so you are not âforcedâ to sell during a decline to meet obligations.
- Extend your time horizon to 5-7 years, as buying distressed stocks can get more distressed.
- Donât obsessively check your portfolio.
- Consider tax-loss harvesting (selling stocks at a loss) to offset those losses against future gains.
- Stick to your investing discipline regardless of what happens.
If I am correct, it is hard to make a case for rising asset prices when a recession occurs. However, if I am wrong, we can reallocate to equities and rebalance our portfolios for growth as needed,
Follow your process.
With so much financial advice out there itâs always hard for me to figure out exactly what to think or actually do. This stuff is good to know I suppose but in the end - when the storm comes - I mostly just Hunker Down and use Retreat to High Ground Theory. But - as an amateur - what the heck do I know?
7 Likes